Update: AstraZeneca Q3 Adjusted Earnings, Revenue Rise; Reaffirms 2026 Outlook
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- AZN Astrazeneca+10.9% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that AstraZeneca belongs to, so it often moves with news about it.
- NVS Novartis AG+1.5% 16d
Novartis AG is a peer of AstraZeneca in pharmaceutical preparations; rivals often move on the same news.
- NVO Novo Nordisk A/S-7.3% 30d
Novo Nordisk A/S is a peer of AstraZeneca in pharmaceutical preparations; rivals often move on the same news.
- GSK Gsk-6.2% 9d
Gsk is a peer of AstraZeneca in pharmaceutical preparations; rivals often move on the same news.
- SNY Sanofi
Sanofi is a peer of AstraZeneca in pharmaceutical preparations; rivals often move on the same news.
- ROIV Roivant Sciences+2.8% 10d
Roivant Sciences is a peer of AstraZeneca in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| AZN | -1.73% | -2.53% | base | +6.87% | +6.93% | after close | after close |
| XLV | -2.61% | -2.65% | base | +0.46% | +0.32% | after close | after close |
| NVS | -6.17% | -2.64% | base | -0.15% | +0.25% | after close | after close |
| NVO | -0.33% | -1.24% | base | +2.15% | +3.32% | after close | after close |
| GSK | +4.27% | +4.73% | base | +1.75% | +0.95% | after close | after close |
| SNY | -3.55% | -2.86% | base | +2.89% | +5.58% | after close | after close |
| ROIV | -2.72% | -2.51% | base | -1.60% | -4.32% | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Update: AstraZeneca Q3 Adjusted Earnings, Revenue Rise; Reaffirms 2026 Outlook Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| AZN | that day | +6.87% | final price |
| AZN | the next day | +6.93% | final price |
| AZN | three days earlier | -2.53% | final price |
| AZN | five days earlier | -1.73% | final price |
| GSK | that day | +1.75% | final price |
| GSK | the next day | +0.95% | final price |
| GSK | three days earlier | +4.73% | final price |
| GSK | five days earlier | +4.27% | final price |
| NVO | that day | +2.15% | final price |
| NVO | the next day | +3.32% | final price |
| NVO | three days earlier | -1.24% | final price |
| NVO | five days earlier | -0.33% | final price |
| NVS | that day | -0.15% | final price |
| NVS | the next day | +0.25% | final price |
| NVS | three days earlier | -2.64% | final price |
| NVS | five days earlier | -6.17% | final price |
| ROIV | that day | -1.60% | final price |
| ROIV | the next day | -4.32% | final price |
| ROIV | three days earlier | -2.51% | final price |
| ROIV | five days earlier | -2.72% | final price |
| SNY | that day | +2.89% | final price |
| SNY | the next day | +5.58% | final price |
| SNY | three days earlier | -2.86% | final price |
| SNY | five days earlier | -3.55% | final price |
| XLV | that day | +0.46% | final price |
| XLV | the next day | +0.32% | final price |
| XLV | three days earlier | -2.65% | final price |
| XLV | five days earlier | -2.61% | final price |
Congressional trades in the stocks in this story
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 64 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 10 Sep 2026. That is 50 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 31 Aug 2026. That is 60 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Scott Scott Franklin bought Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 26 Aug 2026. That is 65 days before publication. Filed 17 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“Update: AstraZeneca Q3 Adjusted Earnings, Revenue Rise; Reaffirms 2026 Outlook” scores 12 out of 100. The score uses 1 sources.